CD274 and neoplasm: The dual blockade of GPR81 by its antagonist, 3-hydroxy-butyrate (3-OBA) and the PD-1/PD-L1 pathway profoundly enhances CTL infiltration and IFN-γ secretion, resulting in tumor regression in animal models in vivo [76].